<i>Pseudomonas aeruginosa</i> infection induces intragraft lymphocytotoxicity that triggers lung transplant antibody-mediated rejection
How pathogens inhibit transplant tolerance remains unclear. Here, we found that <i>Pseudomonas aeruginosa</i> infection, but not other common bacterial respiratory infections, increases antibody-mediated rejection (AMR) risk in recipients of lung transplants. To explore this relationship, we performed orthotopic lung transplants in mice, infected recipients with <i>P. aeruginosa</i>, and observed for the development of AMR. Intravital two-photon microscopy showed that <i>P. aeruginosa</i> rapidly invaded bronchial-associated lymphoid tissues, which resulted in acute lymphocytotoxicity, including the death of forkhead box P3 (Foxp3)<sup>+</sup>CD4<sup>+</sup> T cells that are required to suppress AMR. <i>P. aeruginosa</i>-mediated AMR required expression of the type III secretion system (T3SS), which injects exotoxins into the cell cytoplasm. Through a combination of mutagenesis and epitope tagging experiments, we revealed that T3SS exotoxin T ADP ribosyl-transferase activity was sufficient for graft-resident Foxp3<sup>+</sup>CD4<sup>+</sup> T cell apoptosis, leading to myeloid differentiation primary response 88 (Myd88)-dependent generation of T-box expressed in T cells (T-bet)- and C-X-C motif chemokine receptor 3 (CXCR3)-positive germinal center and memory B cells with high donor antigen avidity. We also found that T-bet<sup>+</sup> and CXCR3<sup>+</sup> B cells were elevated in biopsies from recipients of lung transplants who were diagnosed with AMR. In mice, CXCR3 deficiency restricted to B cells or CXCR3 blockade prevented AMR despite <i>P. aeruginosa</i> infection. Our work has identified a previously unrecognized role of bacterial virulence in lung allograft rejection and suggests potential strategies to prevent AMR for those at high risk of <i>P. aeruginosa</i> infection after transplant.
Authors
- Hrishikesh S. Kulkarni (ORCID: https://orcid.org/0000-0003-4830-5084)
- Marlene Cano (ORCID: https://orcid.org/0000-0002-2368-9256)
- Davide Scozzi (ORCID: https://orcid.org/0000-0002-4049-1591)
- Jothilingam Sivapackiam (ORCID: https://orcid.org/0000-0001-7979-1893)
- Laneshia K. Tague (ORCID: https://orcid.org/0000-0002-6243-1901)
- Dara W. Frank (ORCID: https://orcid.org/0000-0003-1853-3377)
- Daniel Kreisel (ORCID: https://orcid.org/0000-0002-7711-8651)
- Fuyi Liao (ORCID: https://orcid.org/0000-0001-7733-084X)
- Derek E. Byers (ORCID: https://orcid.org/0000-0001-7371-9153)
- Alexander S. Krupnick (ORCID: https://orcid.org/0000-0002-1790-6197)
- Ramsey R. Hachem (ORCID: https://orcid.org/0000-0002-0708-1937)
- Andrew E. Gelman (ORCID: https://orcid.org/0000-0002-0711-6343)
- Wenjun Li (ORCID: https://orcid.org/0000-0002-1923-5016)
- Vijay Sharma (ORCID: https://orcid.org/0000-0002-4985-0044)
- Dequan Zhou (ORCID: https://orcid.org/0009-0009-7288-9981)
- Zhiyi Liu
Institutions
- University of Maryland, Baltimore (US)
- Medical College of Wisconsin (US)
- Washington University in St. Louis (US)
- University of Utah (US)
- Mallinckrodt (United States) (US)
Publication Details
- Journal
- Science Translational Medicine
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1126/scitranslmed.adp1349
- Citations
- 10
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 7.97
Funders
- Children's Discovery Institute
- National Institutes of Health